FIELD: medicine.
SUBSTANCE: invention refers to biotechnology. The method includes the first phase of tumour-responsive CD4+ helpers and/or CD8+ T-lymphocytes stimulation by a tumour antigen together with at least one substance characterised as IL-2 receptor agonist, for increasing the viability of in viability tumour-responsive CD4+ helpers and/or CD8+ T-lymphocytes; and the second phase of tumour-responsive CD4+ helpers and/or CD8+ T-lymphocytes activation and growth intensification where the second phase is initiated by CD25 surface marker (or IL-2R marker) inhibition on CD4+ T-helpers and/or CD8+ T-lymphocytes. This method ensures a great quantity of tumour-responsive T-lymphocytes in a short span of time, and enables the directed evolution of tumour-responsive CD4+ helpers and/or CD8+ T-lymphocytes to specific subpopulations.
EFFECT: improved method for increasing tumour-responsive lymphocyte count and activating, particularly CD4+ helpers and/or CD8+ T-lymphocytes which can be applied in cancer treatment and/or prevention.
18 cl, 28 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
| SYSTEM AND METHOD OF OBTAINING AND STORAGE OF ACTIVATED MATURE DENDRITIC CELLS | 2011 |
|
RU2575978C2 |
| METHOD FOR PRODUCTION OF IN VITRO POPULATIONS OF ACTIVATED ANTIGENSPECIFIC ANTITUMOR-TUMOR CYTOTOXIC T-LYMPHOCYTES SPECIFIC TO TUMOR-ASSOCIATED ANTIGEN EPITOPES | 2016 |
|
RU2619186C1 |
| METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
| EXPANSION OF LYMPHOCYTE WITH A CYTOKINE COMPOSITION FOR ACTIVE CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2739770C2 |
| NEW SUBPOPULATION OF TREG CD8CD45RC CELLS AND ITS APPLICATIONS | 2016 |
|
RU2766691C2 |
| PRODUCTS OF A CERTAIN COMPOSITION CONTAINING GENETICALLY MODIFIED T CELLS | 2015 |
|
RU2751921C2 |
| METHOD FOR STIMULATING PRESENTING ACTIVITY OF DENDRITIC CELLS | 2019 |
|
RU2728592C1 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
